Precision Biosciences’ partner TG Therapeutics has obtained clearance from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application to commence Phase I clinical trial of Azercabtagene Zapreleucel (azer-cel) for progressive forms of multiple sclerosis (MS).
Azer-cel is a new allogeneic CAR T therapy developed by Precision BioSciences.
Go deeper with GlobalData
In January this year, Precision entered a licensing agreement with TG Therapeutics, granting it global rights to azer-cel for autoimmune diseases, excluding cancer indications.
As part of the agreement, Precision BioSciences received an upfront payment along with potential near-term economic benefits valued at $17.5m.
Additionally, the company received up to $288m in milestone payments contingent on the achievement of specific clinical, regulatory, and commercial targets.
Furthermore, Precision BioSciences received royalties on net sales, ranging from high-single-digit to low-double-digit percentages.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataTG Therapeutics plans to initiate the Phase I trial this year to explore the potential of azer-cel in MS treatment.
Precision BioSciences CEO Michael Amoroso said: “We would like to congratulate TG Therapeutics on receiving IND clearance for azer-cel in patients with progressive multiple sclerosis. We believe the expansion of allogeneic CAR T into autoimmune diseases holds the potential to unlock new therapies for patients living with chronic disease.
“We look forward to TG Therapeutics initiating a clinical trial for azer-cel in autoimmune disease as we focus on the advancement of our own wholly owned in vivo gene editing pipeline, including our planned IND and/or clinical trial application (CTA) submission for PBGENE-HBV for hepatitis B this year.”
The company’s ARCUS platform is being used for the development of in vivo gene editing therapies for gene edits.
